Member Info for WeTookPelham

"...Knowlesi - Not a good RNS for you is it?" Lol....it certainly isn't :)

Can someone remind me what this conference is again on Monday, and Scancells involvement please.
Oh and if there's a chance of some "leftfield" news from it :)

I take that back LochinvarLass, as you say it looks like a brand new thing, has a timestamp on the left of "11:47 Mon 20 Jan 2020"

I'd seen that page before, I assume proactive have a snapshot for every company, but i think(?) this one has since changed, the section entitled "Inflexion points" is definitely interesting!
P.s. well spotted!

@7.811p, a buy?

Bermuda i took the liberty of copy and pasting the Trinity view on todays RNS from your link...interesting reading:

"....Trinity Delta view: The AvidiMab technology and associated anti-TaG antibodies are clearly becoming a valuable addition to Scancell’s key existing technology platforms, ImmunoBody and Moditope. Whilst these remain the company’s main assets and have considerable clinical and commercial potential, we see AvidiMab bringing additional near-term value. Initially this may take the form of non-dilutive funding for the ImmunoBody and Moditope clinical programmes; however, successful preclinical evaluations could transform these currently non-exclusive agreements into more meaningful partnerships.

For the time being, and in line with our conservative stance, we have not included AvidiMab in our DCF-based model and maintain our valuation at £82.0m or 17.2p/share."

Doh...thanks, read in haste.

Apologies if this is old news, maybe I just missed this or maybe this is part of a wider North America patent?
Page 340:
https://www.ic.gc.ca/opic-cipo/tmj/eng/25Dec2019_en.pdf?year=2019&edition=12-25

Is that two acquisition/partnership announcements in the space of a few days!? Biontech seem to buying up left right and centre! Now where/when is this deal for Scancell???

Good spot Bermuda. So this at least shows Biontech are in the spending/buying mood following their fund raises/stock listing then??

"On ONE cancer product... an antibody no less!"
"Down the line, Incyte is on the hook for up to $1.1 billion in milestones. '"

I'm sure I've asked a similar question before, but if that's the going rate, what is Scancell worth with it's full suite/pipeline of products?

https://metro.co.uk/2020/01/11/doctor-dies-type-cancer-spent-life-researching-12041935/

...And just to add, they clearly need more (skilled) hands on deck then, and soon too?

Great spot Crumbs.
From the job description:
"Scancell is conducting a phase II clinical trial of the DNA ImmunoBody® vaccine SCIB1 for treatment of melanoma, with a Moditope® phase I/II trial soon to start."

"...There is no chance that 2.925m trade was a buy. The SP would have reacted significantly.
All you are seeing is balancing of the books from the 5p Share Subscription and Issue of Equity to Vulpes.
The gap has been filled"

I might have that framed and laminated.

...all the tiny sells?

https://www.bbc.co.uk/news/health-50507069

I think I'm right in saying that Scancell don't always RNS when they are attending conferences/giving presentations?
So just curious as to others thoughts as to why this one was? Or maybe they thought they'd just throw it in with the patent news!?

...again? Haven't been paying too much attention if im honest so don't know it's its been like that for a while? But either way it's as low as it seems to get right?

Thanks Bermuda, much appreciated, that makes a lot more sense now.

This paragraph you wrote at least gives a little bit of positivity/hope!
"....We now know the European Enolase patent is about to be granted which must give hope for the US counterpart. Also the European divisional application for the DNA version of Moditope has recently been re-examined and revised claims were submitted at the end of October. Hopefully that one is now very close to being granted too."